AvalehtMCRPF • OTCMKTS
add
MicroPort Scientific Corp
Viimane sulgemishind
1,51 $
Aasta vahemik
0,65 $ - 1,85 $
Turuväärtus
21,44 mld HKD
Keskmine maht
553,00
P/E suhe
-
Dividendimäär
-
Põhibörs
HKG
Börsiuudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | juuni 2025info | Y/Y muutus |
|---|---|---|
Käive | 273,77 mln | −2,00% |
Põhitegevusega seonduv kulu | 153,68 mln | −14,80% |
Puhastulu | −23,30 mln | 51,87% |
Puhaskasumimarginaal | −8,51 | 50,89% |
Puhaskasum aktsia kohta | — | — |
EBITDA | 26,04 mln | 99,76% |
Tõhus maksumäär | −86,95% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | juuni 2025info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 957,62 mln | −7,63% |
Kogu vara | 3,77 mld | −0,59% |
Kõik kohustused | 2,59 mld | 3,36% |
Kogu omakapital | 1,18 mld | — |
Emiteeritud aktsiate arv | 1,85 mld | — |
Hinna ja väärtuse suhe P/B | 4,44 | — |
Varade tasuvus | 0,04% | — |
Kapitali tasuvus | 0,05% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | juuni 2025info | Y/Y muutus |
|---|---|---|
Puhastulu | −23,30 mln | 51,87% |
Põhitegevuse rahakäive | −5,77 mln | 65,49% |
Investeeringute raha | −3,17 mln | 96,31% |
Finantseerimise raha | 33,95 mln | 201,05% |
Raha ja raha ekvivalentide muutus | 25,75 mln | 118,43% |
Tasuta rahavoog | 12,88 mln | 421,18% |
Teave
MicroPort is a multinational medical technology company with headquarters in Shanghai; Irvine, California; and Clamart, France. Founded in 1998, the company designs and produces medical devices across multiple therapeutic areas including interventional cardiology, orthopedics, cardiac rhythm management, electrophysiology, neurovascular intervention, structural heart disease, surgical robotics, and critical care.
MicroPort completed its initial public offering on the Hong Kong Stock Exchange in 2010 and has since established multiple specialized subsidiaries focused on distinct therapeutic areas, with several completing separate public listings. Recognized as one of the global Medtech Big 100 companies, MicroPort's coronary intervention products have been implanted in over 10 million patients globally since its founding, with devices distributed in over 90 countries across Asia, North America, Latin America, Europe, the Middle East, and Africa. Wikipedia
Tegevjuht
Asutatud
1998
Veebisait
Töötajate arv
6 287